Kiora Pharmaceuticals
KPRX on Nasdaq. Market value $5m.
Should I look at this?
Look carefully before going further
Why it could be worth it
Nothing stands out yet.
What to watch out for
Read the warning sign in its own filings
This is not advice.
Who owns it
None of the long-term investors we follow own it. 22 funds in all.
Largest holders overall
- Perceptive Advisors$1mNew
- ADAR1 Capital Management$441,685
- Citadel Advisors$305,109Added
- TWO Sigma Investments, LP$233,523New
- Millennium Management$195,151New
- HRT Financial LP$154,000New
- Renaissance Technologies$78,437New
- Geode Capital Management$70,264Cut
- Vanguard Capital Management$52,234
- Scientech Research$49,302New
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
7 investors own more than 5%.
- Nantahala Capital Management, LLCPassive investorat least 10.0%0.0 pts(filed with 2 related holders)Since 30 June 2026
- Perceptive Advisors LLCPassive investorat least 10.0%(filed with 2 related holders)Since 6 April 2026
- ADAR1 Capital Management, LLCPassive investorat least 9.9%0.0 pts(filed with 2 related holders)Since 30 June 2026
- Rosalind Advisors, Inc.Passive investorat least 9.9%0.0 pts(filed with 3 related holders)Since 31 December 2025
- Baselake Partners, LPPassive investorat least 5.8%(filed with 2 related holders)Since 10 September 2026
- Alyeska Investment Group, L.P.Passive investorat least 5.0%−5.0 pts(filed with 2 related holders)Since 30 September 2026
- Orin HirschmanPassive investorat least 4.9%−3.6 pts(filed with 1 related holder)Since 31 December 2025
- NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIPPassive investorSold down below 5%Since 31 March 2026
- THE GOLDMAN SACHS GROUP, INC.Passive investorSold down below 5%Since 31 December 2024
| Holder | Stake | Since | |
|---|---|---|---|
Nantahala Capital Management, LLC Passive investor | at least 10.0%0.0 pts (filed with 2 related holders) | 30 June 2026 | |
Perceptive Advisors LLC Passive investor | at least 10.0% (filed with 2 related holders) | 6 April 2026 | |
ADAR1 Capital Management, LLC Passive investor | at least 9.9%0.0 pts (filed with 2 related holders) | 30 June 2026 | |
Rosalind Advisors, Inc. Passive investor | at least 9.9%0.0 pts (filed with 3 related holders) | 31 December 2025 | |
Baselake Partners, LP Passive investor | at least 5.8% (filed with 2 related holders) | 10 September 2026 | |
Alyeska Investment Group, L.P. Passive investor | at least 5.0%−5.0 pts (filed with 2 related holders) | 30 September 2026 | |
Orin Hirschman Passive investor | at least 4.9%−3.6 pts (filed with 1 related holder) | 31 December 2025 | |
NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP Passive investor | Sold down below 5% | 31 March 2026 | |
THE GOLDMAN SACHS GROUP, INC. Passive investor | Sold down below 5% | 31 December 2024 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
No insider bought or sold on the open market in the last 12 months.
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
1 serious warning sign in Kiora Pharmaceuticals’ filings.
We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.
We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 25 Mar 2026, plus the 10-Q filed 12 Nov 2026 and 10 later 8-Ks.
Doubt it can keep going
SeriousThe company or its auditor warned it may not have enough money to last the next year.
“The factors described above have caused management to determine there is substantial doubt about the Company’s ability to continue as a going concern.”
Show the full paragraph
Cash Equivalents of $ 5.6 million and Short-term Investments of $ 10.7 million, and an Accumulated Deficit of $ 160.5 million. Subsequent to the reporting period, in October 2026, the Company entered into a license agreement with Senju Pharmaceutical Co., Ltd. (“Senju”), (the "KIO-401 License Agreement"), under which the Company will pay Senju a $ 3.5 million upfront payment and a $ 12.5 million technology transfer milestone (see Note 13). With the exception of the year ended December 31, 2024, Kiora has incurred annual losses and negative cash flows since inception, and future losses are anticipated. Based on the cash and short-term investments on hand at September 30, 2026, the Company anticipates having sufficient cash to fund its planned operations into late 2027, excluding the technology transfer milestone, which may become payable prior to such date. The acceleration or reduction of cash outflows by management can significantly impact the timing for the need to raise capital to complete development of its products. To continue development, Kiora will need to raise additional capital through equity financing, license agreements, and/or grants. Although historically the Company has been successful at raising capital, most recently raising net proceeds of approximately $ 4.9 million in a private offering that closed on April 6, 2026, as well as an equity line of credit that provides an additional $ 10 million (subject to certain limitations), additional capital may not be available on terms favorable to Kiora, if at all. The Company does not know if any future offerings will succeed. Accordingly, no assurances can be given that Company management will succeed in these endeavors. The factors described above have caused management to determine there is substantial doubt about the Company’s ability to continue as a going concern. The accompanying condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities or any other adjustments that might be necessary should the Company be unable to continue as a going concern
From the 10-Q filed 12 November 2026, Part I, Item 1. Financial Statements. Read it in the filing
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.